Adverse Events Should Not Be Surprising in Psychedelic Research
- 27 February 2025
- journal article
- Published by SAGE Publications in Psychedelic Medicine
- Vol. 3 (1) , 59-62
Abstract
Research has demonstrated both risks and benefits to using psychedelics as a therapeutic intervention for a variety of mental health conditions. In recent years, the public discourse around psychedelic treatments has been largely positive and focused on benefits more than risks. We believe the field would benefit from more balanced attention to the risks as well as benefits of psychedelics within the scientific community and broader public. Coverage of psychedelic science has swung between a pendulum of extremes, from fearmongering in past decades to effusive optimism today. Public discourse about the risks and benefits of psychedelics can and should instead be grounded in the growing evidence from clinical trials as well as participant reports. While most adverse events related to pyschedelics are mild, some have been severe and serious, and public education about the existence and nature of those risks is necessary. We predict that as more studies are conducted and eligibility criteria are relaxed to improve access, the incidence and severity of adverse events will increase. While no medical intervention is risk-free, it will be increasingly important to quantify and effectively communicate the risk/benefit profile of psychedelics.Keywords
This publication has 20 references indexed in Scilit:
- The Hopkins-Oxford Psychedelics Ethics (HOPE) Working Group Consensus StatementThe American Journal of Bioethics, 2024
- Case analysis of long-term negative psychological responses to psychedelicsScientific Reports, 2023
- Studying Harms Is Key to Improving Psychedelic-Assisted Therapy—Participants Call for Changes to Research LandscapeJAMA Psychiatry, 2023
- Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of lifeJournal of Affective Disorders, 2023
- Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case reportHeliyon, 2022
- Preparing for the Bursting of the Psychedelic Hype BubbleJAMA Psychiatry, 2022
- Lysergic Acid Diethylamide–Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II StudyBiological Psychiatry, 2022
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use DisorderJAMA Psychiatry, 2022
- United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006–2020International Journal of Drug Policy, 2022
- Psychedelic Knowledge and Opinions in Psychiatrists at Two Professional Conferences: An Exploratory SurveyJournal of Psychoactive Drugs, 2021